Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis

American Journal of Ophthalmology

Volumn 136, Issue 6, 2003, Pages 1097-1105

  Greiner, Jack V ^a   Mundorf, Thomas ^b   Dubiner, Harvey ^c   Lonsdale, John ^b   Casey, Richard ^d   Parver, Leonard ^b   Kapik, Barry M ^e   Shams, Naveed B K ^e   Abelson, Mark B ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b Presbyterian Medical Tower ^*  (United States)

^c Clayton Eye Center   (United States)

^d JULES STEIN EYE INSTITUTE   (United States)

^e Novartis Ophthalmics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOTIFEN FUMARATE;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BURNING SENSATION; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PHARYNGITIS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RHINOCONJUNCTIVITIS; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER;

EID: 0344441354     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)00708-6     Document Type: Article

References (30)

1. Abelson M.B. Allergic diseases of the eye. 2001;WB Saunders Company, Philadelphia.
2. Abelson M.B., Chapin M.J. Current and future topical treatments for ocular allergy. Compr Ophthalmol Update. 1:2000;303-320.
3. Kinet J.P. The high-affinity receptor for immunoglobulin-E: Structure, function, and role in allergy. Gallin J.I., Goldstein I.M., Snyderman R. Inflammation: Basic principles and clinical correlates. 2nd ed :1992;702-705 Raven Press, New York.
4. Allansmith M.R. Immunology of the eye. Allansmith M.R. The eye and immunology. 1982;99-115 Mosby, St. Louis.
5. Abelson M.B., Chambers W.A., Smith L.M. Conjunctival allergen challenge A clinical approach to studying allergic conjunctivitis . Arch Ophthalmol. 108:1990;84-88.
6. Chand N., Pillar J., Diamantis W., Sofia R.D. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions. 16:1985;318-322.
7. Yamaguchi T., Sato Y., Fukushige J., Fukami M., Lizuka Y. Effects of ketotifen fumarate eye drops on experimental conjunctivitis in rats and guinea pigs. Iyakuhin Kenkyu. 20:1989;48-56.
8. Elena PP, Amar T, Schoch C. Comparison of efficacy between ketorolac and ololpatadine eye drops in allergic conjunctivitis. Invest Ophthalmol Vis Sci 1998;39:S549.
9. Martin U., Römer D. The pharmacological properties of a new, orally active antianaphylactic compound Ketotifen, a benzocycloheptathiophene . Arzneimittelforschung. 28:1978;770-782.
10. Miki I., Kusano A., Ohta S., et al. Histamine enhanced the TNF-α-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cell Immunol. 171:1996;285-288.
11. Lai C.K.W., Ollier S., Lau C.K., Holgate S.T. Effect of azelastine and ketotifen on the bronchial and skin responses to platelet-activating factor in humans. Clin Exp Allergy. 21:1991;489-496.
12. Devillier P., Arnoux B., Lalau Keraly C., Landes A., Marsac J., Benveniste J. Inhibition of human and rabbit platelet activation by ketotifen. Fundam Clin Pharmacol. 4:1990;1-9.
13. Saeed S.A., Mahmood F., Naqvi A., Jafary M.H. Inhibitory effect of oral ketotifen on ex vivo platelet activating factor -induced platelet aggregation. Agents Actions. 34:1991;351-357.
14. Kahhak L., Roche A., Dubray C., Arnoux C., Benveniste J. Decrease of ciliary beat frequency by platelet activating factor Protective effect of ketotifen . Inflamm Res. 45:1996;234-238.
15. Sanjar S., Smith D., Schaeublin E., et al. The effect of prophylactic anti-asthma drugs on PAF-induced airway hyperreactivity. Jpn J Pharmacol. 51:1989;151-160.
16. Nabe M., Miyagawa H., Agrawal D.K., Sugiyama H., Townley R.G. The effect of ketotifen on eosinophils as measured by LTC4 release and by chemotaxis. Allergy Proc. 12:1991;267-271.
17. Sugiyama H., Nabe M., Miyagwa H., Agrawal D.K., Townley R.G. Inhibitory effect of ketotifen on LTC4 release and eosinophil chemotaxis. J Allergy Clin Immunol. 85:(Suppl 1):1990;. S549-281.
18. Grant S.M., Goa K.L., Filton A., Sorkin E.M. Ketotifen, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma and allergic disorders. Drugs. 40:1990;412-448.
19. Sanjar S., Aoki S., Boubekeur K., et al. Eosinophil accumulation in pulmonary airways of guinea pigs induced by exposure to an aerosol of platelet-activating factor Effect of anti-asthma drugs . Br J Pharmacol. 99:1990;267-272.
20. Sanjar S., Aoki S., Boubekeur K., et al. Inhibition of PAF-induced eosinophil accumulation in pulmonary airways of guinea pigs by anti-asthma drugs. Jpn J Pharmacol. 51:1989;167-172.
21. Arnoux B., Denjean A., Page C.P., Nolibe D., Morley J., Benveniste J. Accumulation of platelets and eosinophils in baboon lung after PAF-acether challenge Inhibition by ketotifen . Am Rev Respir Dis. 134:1988;855-860.
22. Morita M., Tsuruta S., Mori K.J., Mayumi M., Mikawa H. Ketotifen inhibits PAF-induced actin polymerization in a human eosinophilic leukaemia cell line, EoL-1. Eur Respir J. 3:1990;1173-1178.
23. Soto J., Tchernitchin A.N., Poloni P., Voigt G., Caro B., Agurto M. Effects of ketotifen on the distribution and degranulation of uterine eosinophils in estrogen treated rats. Agents Actions. 28:1989;198-203.
24. Woerly G., Loiseau S., Loyens M., Schoch C., Capron M. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils consequences for allergic eye diseases . Allergy. 58:2003;397-406.
25. Ohmori K., Manabe H., Akuta-Ohnuma K. Inhibitory effect of oxatomide on oxygen-radical generation and peptide-leukotriene release from guinea pig eosinophils. Arzneimittelforschung. 48:1998;43-46.
26. Mita H., Shida T. Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen, and oxatomide in human leukocytes. Arzneimittelforschung. 45:1995;36-40.
27. Agresti A. An introduction to categorical data analysis. 1996;227-231 John Wiley & Sons, New York.
28. Abelson M.B., Chapin M.J., Kapik B.M., Shams N.B. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol. 121:2003;626-630.
29. Berdy G.J., Spangler D.L., Bensch G., Berdy S.S., Brusatti R.C. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther. 22:2000;826-833.
30. D'Arienzo P.A., Leonardi A., Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther. 24:2002;409-416.